Editorial Board — Medscape Pulmonary Medicine


James F. Donohue, MD
James F. Donohue, MD

Professor of Medicine, School of Medicine, University of North Carolina, Chapel Hill

James F. Donohue, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Novartis; Sunovion Pharmaceuticals
Received income in an amount equal to or greater than $250 from: AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Novartis; Sunovion Pharmaceuticals


Nicholas J. Gross, MD, PhD
Nicholas J. Gross, MD, PhD

Professor Emeritus, Stritch-Loyola School of Medicine, University of Chicago School of Medicine, Hyde Park, Chicago, Illinois; Volunteer Physician, St. Francis Hospital, Hartford, Connecticut

Nicholas J. Gross, MD, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Mylan Laboratories Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP
Serve(d) as a speaker or a member of a speakers bureau for: Mylan Laboratories Inc.


Aaron B. Holley, MD

Associate Professor, Department of Medicine, Uniformed Services University, Bethesda, Maryland; Chief, Pulmonary Service, San Antonio Military Medical Center, San Antonio, Texas

Aaron B. Holley, MD, has disclosed the following relevant financial relationships:
Received a research grant from: Fisher-Paykel; Department of Defense
Received income in an amount equal to or greater than $250 from: American College of Chest Physicians


Steven Nathan, MD
Steven Nathan, MD

Professor of Medicine, Virginia Commonwealth University; Medical Director, Advanced Lung Disease Center, Inova Fairfax Hospital, Falls Church, Virginia

Steven D. Nathan, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Boehringer-Ingelheim Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals; Gilead Sciences, Inc.; aTyr Pharma Inc.; Bellerophon Therapeutics; Genentech-Roche; United Therapeutics Corporation
Serve(d) as a speaker or a member of a speakers bureau for: Boehringer-Ingelheim Pharmaceuticals; Bayer HealthCare Pharmacuticals; Gilead Sciences, Inc.; Genentech-Roche
Received research grant from: Boehringer-Ingelheim Pharmaceuticals; Bayer HealthCare Pharmaceuticals; Gilead Sciences, Inc.; Genentech-Roche; United Therapeutics Corporation
Received income in an amount equal to or greater than $250 from: Boehringer-Ingelheim Pharmaceuticals; Bayer HealthCare Pharmaceuticals; Gilead Sciences, Inc.; aTyr Pharma Inc.; Bellerophon Therapeutics; Genentech-Roche; United Therapeutics Corporation


Andrew F. Shorr, MD, MPH
Andrew F. Shorr, MD, MPH

Professor of Medicine, Georgetown University; Director, Section of Pulmonary & Critical Care Medicine; Director, Medical Intensive Care Unit, Medstar Washington Hospital Center, Washington, DC

Andrew Shorr, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a consultant, speaker, or has received research support from: AstraZeneca Pharmaceuticals LP; Astellas Pharma, Inc; Actavis; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company; Merck & Co. Inc; Pfizer Inc; Roche; Tetraphase; Theravance, Inc.; Achaogen; Shinogi; MedCo
Received research grant from: Astellas Pharma; Merck & Co. Inc; MedCo